06:22 AM EDT, 09/17/2025 (MT Newswires) -- Celldex Therapeutics ( CLDX ) said Wednesday that new data from a study of barzolvolimab showed rapid and strong efficacy regardless of baseline immunoglobulin E levels in patients with chronic spontaneous urticaria.

The results showed similar improvements in urticaria activity scores and rates of disease control in both low and normal or high immunoglobulin E subgroups at 12 and 52 weeks, Celldex said.

Celldex also said it is enrolling patients for two phase 3 trials to further evaluate the safety and efficacy of barzolvolimab.